Arcutis Biotherapeutics Inc Stock News

WESTLAKE VILLAGE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 21,000 restricted stock units of Arcutis' common stock to three newly hired employees.

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Frank Watanabe - Corporate Participant Latha Vairavan - Corporate Participant Patrick E. Burnett - Executive VP & Chief Medical Officer Todd Edwards - Corporate Participant Conference Call Participants Lin Tsai - Jefferies LLC, Research Division Richard J.

Arcutis (ARQT) Q2 Revenue Soars 164%

Q2 2025 net product revenue for ZORYVE® (roflumilast) was $81.5 million, a 164% increase compared to Q2 of 2024, and a 28% increase compared to Q1 of 2025, driven by strong portfolio demand growth ZORYVE foam 0.3% received U.S. Food and Drug Administration (FDA) approval for the treatment of plaque psoriasis of the scalp and body in adults and adolescents 12 years of age and older Initiated INT...

Upgrading Arcutis Biotherapeutics, Inc. from Hold to Buy due to Zoryve's strong regulatory and commercial momentum, with revenue and prescription growth exceeding expectations. Zoryve's expanding label, superior safety profile, and new foam formulation position it as a potential new standard of care in plaque psoriasis and atopic dermatitis. ARQ-255's upcoming Phase Ib results could unlock a fi...

Arcutis announced today that it will report Q2 2025 financial results and provide a business update on Aug 6, 2025 after the U.S. financial markets close.

Arcutis stock is setting up in a base with the company's earnings report due around mid-August.

WESTLAKE VILLAGE, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 14,000 restricted stock units of Arcutis' common stock to two newly hired employees. These awards were approved by the Compensation Co...